Novel INK4C inhibitor, specifically blocking the bioactivity of p18 protein

Novel INK4C inhibitor, specifically blocking the bioactivity of p18 protein

Second-generation active site-targeted covalent irreversible inhibitor of USP7

Novel potent inhibitor of mTOR activity, significantly suppressing macroscopic and histologic abnormalities associated with chemically-induced murine ulcerative colitis.

Novel P2Y1 Antagonist

Selective spleen tyrosine kinase (SYK) inhibitor, suppressing leukocyte immune function and inflammation, and leading to a reduction in arthritis score and attenuated histological damage

Novel modulator of p53 activity, arresting at G2/M phase inducing delay of cell cycle progression

Novel reactivator of mutant p53, fuctioning as a zinc metallochaperone (ZMC) with diminished copper binding that functions as a chemotherapy and radiation sensitizer

Novel inhibitor of atherogenesis and diabetes, significantly and specifically inhibiting αD-CEP binding

Novel bFGF antagonist peptide, inhibiting breast cancer cell growth

Neuroprotective agent, protecting ventral horn spinal cord motor neurons from cell death

Novel potent inhibitor of the AAA+ ATPase p97

Novel potent inhibitor of the AAA+ ATPase p97

Pseudomonas aeruginosa autoinducer

Novel partial agonist of peroxisome proliferator-activated receptor-γ (PPARγ), recruiting PPARγ-coactivator-1α, preventing triglyceride accumulation, and potentiating insulin signaling in vitro

Photoswitchable epithelial sodium channel (ENaC) blocker

Novel glutathione-S-transferase-p-activated nitric oxide donor, inhibiting proliferation and inducing apoptosis by targeting PI3K/AKT/mTOR and MEK/ERK pathways in hepatocellular carcinoma cells

Novel potent and selective inhibitor of protein arginine deiminase 3 (PAD3), having 15600 kinact/KI values and ≥10-fold selectivity for PAD3 over PADs 1, 2, and 4.

Partial DAT/5-HT transporter substrate

Full DAT/5-HT transporter substrate

Novel selective LYPLAL1 activator, increasing LYPLAL1’s catalytic activity likely by enhancing the efficiency of the catalytic triad charge-relay system, confering beneficial effects in a mouse model of diet-induced obesity

Full DAT/5-HT transporter substrate; Non-neurotoxic releasing agent of serotonin, norepinephrine, and dopamine; Full agonist at 5-HT2B and partial agonist at 5-HT2C

Potent dual dopamine-serotonin (DA/5-HT) releaser

Selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6

Novel Ras-Signaling Modulator, targeting acyl protein thioesterase 1 (APT1) and 2 (APT2) in cells

Potent serotonin-3 (5-HT3) receptor antagonist

Novel TLR2 agonist as potential adjuvant for cancer vaccines

Inhibitor of the Cell_cycle>cell cycle from G0/G1 to S phase with powerful antiparasite activity

Biological Active Reagents

Tamoxifen analogue; antiestrogenic

Novel potent pan-Raf and receptor tyrosine kinase inhibitor, potently inhibits all subtypes of Rafs with IC50 values of 3.49 (BRafV600E), 8.86 (ARaf), 5.78 (BRafWT), and 1.65 nM (CRaf), respectively

Potent and highly selective small molecule inhibitor of thioredoxin reductase (TrxR)

Pathway Preferential Estrogen, activating the extranuclear signaling pathway without activity on the nuclear signaling pathway

Blebbistatin derivative, increasing water solubility, decreases the inherent fluorescence, stabilizing the molecule to circumvent its degradation by prolonged blue light exposure, and decreasing its phototoxicity while retaining the in vitro and in vivo a

Isomer of CID-5951923

Selective cell-permeable inhibitor of non-muscle myosin II ATPases, being more stable and less phototoxic than Blebbistatin

Acetylcholinesterase inhibitor, the active metabolite of the insecticide parathion

Non-selective contact herbicide, killing green plant tissue on contact, being highly toxic and linked to Parkinson's disease, generating reactive oxygen species (ROS), which causes cell death and potentially leading to acute respiratory distress syndrome

Novel potent phosphodiesterase 3 inhibitor, suppressing the asthmatic response and showing both bronchodilating and anti-inflammatory effects

Novel potent phosphodiesterase 3 inhibitor, suppressing the asthmatic response and showing both bronchodilating and anti-inflammatory effects

Potent and Novel Dual PARP/BRD4 Inhibitor for Efficient Treatment of Pancreatic Cancer

Novel highly selective dual PARP1/BRD4 inhibitor (PARP1 IC 50 =49nM; BRD4 IC 50 =202nM), repressing the expression and activity of PARP1 and BRD4 to synergistically inhibit the malignant growth of pancreatic cancer cells in vitro and in vivo

Novel Selective Cell-Active Inhibitor of PARP10

Fluorescent PARP1 Inhibitor for Glioblastoma Imaging

Natural ent-kaurane diterpenoid, markedly stimulates the expression of NKG2D ligands on hepatocellular carcinoma (HCC) cells, considerably enhancing their recognition and lysis by NK cells, covalently inhibiting peroxiredoxins I/II (Prxs-I/II) catalytic a

Novel antiviral agent, potently against Rabies virus (RABV) targeting host-rabies virus protein-protein interactions

Partial agonist at GABAA benzodiazepine receptors with sedative and anxiolytic effects

Novel potent inhibitor of

Novel potent glucosidase inhibitor, suppressing HCV virion assembly and secretion, potently inhibiting DENV infection in vitro

Novel Inhibitor of Parasite Proliferation of Asexual Blood Stage P. falciparum Parasites

Novel Inhibitor of Parasite Proliferation of Asexual Blood Stage P. falciparum Parasites

Novel enhancer of Th1 type cytokine production and primary T cell activation

Pyridobenzimidazole infraluciferin, an analog of D-luciferin, increasing bioluminescence activity while maintaining nIR bioluminescence

Novel αvβ3 inhibitor, showing excellent efficacy in a glioblastoma multiforme (GBM) mouse model

Novel dual inhibitor of the canonical and noncanonical NF-κB pathways, increasing the magnitude and duration of initial EGFR inhibitor response in multiple NSCLC models, decreasing PDHK1 expression, and suppressing phosphorylation of the PDHK1 protein sub

Novel calcineurin inhibitor in the C. albicans cells, enhancing susceptibility of the cells

Potent tubulin-binding agent with anti-tumor efficacy in hematologic cancers

Water-soluble novel potential COX-2 inhibitor

Non-dioxin-like (NDL) congener

Novel Chelator for Cu-64

Novel PSD95-nNOS inhibitor, disrupting the PSD95-nNOS interaction, attenuating neuropathic pain, decreasing SNL-induced spinal dorsal horn WDR neuron hyperexcitation

Novel activator of effector T cells, enhancing T cell proliferation and activation to release interferon gamma (IFN-γ) and interleukin-2 (IL-2) without blocking the programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) binding and not dire

Novel α7 nAChR weak partial agonist, showing antinociceptive and anti-inflammatory properties

Organoselenium compound with antidepressant-like and memory enhancer actions

Potent antagonist of the series disrupting EphA2-ephrinA1 interaction, blocking EphA2 phosphorylation in prostate cancer cells at low

Highly selective α1L adrenaline receptor agonist

Novel potent dopamine D3R agonist (Ki=4.1nM)

Novel potent and selective dopamine D3R partial agonist

Novel potent dopamine D3R antagonist

Novel modulator of proprotein convertase subtilisin kexin like type 9 (PCSK9)

Novel PCSK9 mRNA translation inhibitor

Novel PCSK9 mRNA translation inhibitor

Novel liver-targeted inhibitor of ribosomal synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9)

Novel inhibitor of PD-I/PD-L1 interaction to be used as a negative immune checkpoint regulatory and antineoplastic agent

Novel potent PD-1/PD-L1 antagonist (IC50 of 16.17 nM), activating the antitumor immunity of T cells efficiently in PBMCs

Novel bifunctional inhibitor of PD-1/PD-L1 interactions, promoting dimerization, internalization, and degradation of PD-L1, suppressing tumor growth in vivo by activating antitumor immunity

Novel Potent Inhibitor of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

Novel inhibitor of PD-1/PD-L1 (IC 50 value of 56.58 nM), dose-dependently promoting HepG2 cell death in a co-culture model of HepG2/hPD-L1 and Jurkat T cells, effectively inhibiting tumor growth (TGI of 76.4% at 90 mg/kg) in an immune checkpoint humanized

Novel potent programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitor (IC50 9.1 nM)

Selective D3 dopamine receptor agonist

Selective antagonist for human ETA receptors

Neuropeptide Y Y1 receptor antagonist

AMPA receptor antagonist

AMPA receptor antagonist

Novel, potent, and selective NR1/2B NMDA receptor antagonist

Novel cell specific photoswitchable agonist for reversible control of endogenous dopamine receptors

Novel selective inhibitor of STAT3 phosphorylation, binding to the SH2 domain of STAT3, exhibiting remarkable antiproliferative activity against three cancer cell lines (HCT-116, SW480 and MDA-MB-231)

Novel inducer of mitotic arrest and apoptosis in human progenitor and cancer cells

Novel G6PD inhibitor

Potent and selective second-generation phosphodiesterase type 5 (PDE5) inhibitor

Novel cell-permeable PDE7 inhibitor, targeting the cyclic adenosine monophosphate (cAMP)/cAMP-response element binding protein (CREB) pathway, exerting neuroprotection in an Alzheimer's disease (AD) model

Novel selective PDE9 inhibitor with strong antioxidant activity, inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer’s disease

Novel Potent, Selective, and Orally Bioavailable Inhibitor against Phosphodiesterase-9 (PDE9)

Novel inhibitor of melanogenesis

Novel Peptide Deformylase (PDF) Inhibitor

Protein disulfide isomerase (PDI) inhibitor

Novel PD-L1 degrader, showing 66.99% degradation activity at 20 μM with no calcium blocking effect, strengthening the T cell-mediated killing of tumor cells

Novel PROTAC dual inhibitor and degrader of PD-L1, inhibiting PD-1/PD-L1 interaction with IC50 of 39.2 nM in an HTRF binding assay

Novel Potent PD-L1 Inhibitor (IC50 1.8 nM), binding to human PD-L1 (hPD-L1) with a KD value of 3.34 nM, without showing any binding to hPD-1, blocking PD-1/PD-L1 interaction with an EC50 value of 375 nM

Novel pendrin inhibitor, inhibiting Cl-/anion exchange mediated by mouse pendrin without affecting other major kidney tubule transporters

Novel polyethylene glycol (PEG)-drug conjugate of Venetoclax, a Bcl-2 inhibitor, for treatment of acute myeloid leukemia (AML)

Activator of SHIP-1

Cyclooxygenase Inhibitor and Prostagladin Synthase Inhibitor

Novel caged glutamate

Antineoplastic agent, alkylating and crosslinking DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis

Mycotoxin with antibiotic and carcinogenic activity

Antibiotic, a natural penicillin, synthesized in vitro by incubating (S-octanoyl)glutathione, 6-APA and AT

Novel potent and broad-spectrum anti-influenza A virus (anti-IAV) activities with low risk of inducing drug resistance

Inhibitor of calcium-dependent complex formation with p53 [(Ca)S100B-p53] in malignant melanoma (MM), restoring p53 tumor suppressor activity in vivo

Innate defense regulator, target stringent response-controlled virulence in a Pseudomonas aeruginosa murine cutaneous infection model

ApoA-I/HDL mimetic peptide, efficiently crossing the blood-brain barrier and modulating amyloid beta distribution between brain and plasma

Broad-spectrum virus- and host-targeting peptide, inhibiting coronaviruses and other respiratory viruses

Agonist of dopamine receptor subtypes D1 and D2

Exceptionally Potent and Membrane-Embedded Inhibitor of Bilayer Lipid Peroxidation

Non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor

Novel allosteric inhibitor of E. coli Hsp70 (DnaK) and human Hsp70 proteins

First Inhibitor of PEX14-PEX5 Protein-Protein Interaction (PPI) with Trypanocidal Activity

Novel γ-secretase inhibitor

Dose dependent inhibitor of multiple fibrotic genes

Selective dopamine D3/D2 receptor antagonist

Novel potent and selective PDE8B/8A inhibitor

Irriversible inhibitor of kynurenine amino transferase II (KAT II)

Novel selective hTRPV4 Antagonist (hTRPV4 IC50 49nM; rTRPV4 IC50 1,150nM)

Novel potent TRPV4 antagonist (hTRPV4 IC50 4nM; rTRPV4 IC50 27nM)

Novel potent and highly selective leucine rich repeat kinase 2 (LRRK2) inhibitor

Potent and selective inhibitor of diacylglycerol acyltransferase 2 (DGAT2)

Novel non-brain-penetrant long-acting peptide oxytocin (OT) receptor agonist with increased selectivity for the OT receptor and significantly increased pharmacokinetic stability

Novel potent and selective inhibitor of MAP4K4

Novel tyrosine residues probe, rationally targeting active site

Novel potent and selective inhibitor of MAP4K4

PF-06835919, also known as MDK1846, is a potent ketohexokinase (KHK) inhibitor. PF-06835919 is reported in patent US 20170183328 A1, example 4. Increased fructose consumption and its subsequent metabolism have been implicated in hepatic steatosis, dyslipidemia, obesity, and insulin resistance in humans. Since ketohexokinase (KHK) is the principal enzyme responsible for fructose metabolism, identification of a selective KHK inhibitor may help to further elucidate the effect of KHK inhibition on these metabolic disorders.

Novel prdrug of PF-06843195, a potent PI3Kα-selective inhibitor

Novel SAM Competitive PRMT5 Inhibitor, Demonstrating Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

Natural cyclic tetrapeptide HDAC Inhibitor through the inhibition of PfHDAC1 catalytic activity, potently inducing the synthesis of metallothionein

Potent, selective non-peptidic antagonist of the V1a receptor

Novel dual H3/4 histamine receptor antagonist

Highly selective, extremely potent Mps1 kinase inhibitor

Potent and selective 5-HT2C receptor agonist

Selective and potent PDK1 inhibitor inducing anti-tumor activity in breast cancer cells

Novel, potent and specific inhibitor of sphingosine kinase-1 (SphK1)

Antimalarial, actively against Plasmodium liver stages

Potent, ATP-competitive, reversible inhibitor of FAK

Novel potent and selective inhibitor of the activation-loop mutant Kit phosphorylation and tumor growth

Novel Entry Inhibitor of both CCR5- and CXCR4-Tropic Strains of Human Immunodeficiency Virus Type 1 (HIV-1), Targeting a Novel Site on gp41

Highly selective, extremely potent Mps1 kinase inhibitor

Novel fluorophosphonate-based probe, specifically and covalently reacts with the tyrosine-111 residue of the Schistosoma japonicum GST (sjGST) tag, rapidly and site-selectively immobilizes sjGST fusion proteins

Novel dual CBP/p300 and BRD4 bromodomain inhibitor, downregulating IL-6, IL-ß and IFN-ß in macrophages

Negative control for PFI-7 (GLXC012596)

Novel selective inhibitor of both Plasmodium and Cryptosporidium lysyl-tRNA synthetase, clearing parasites from mouse models of malaria and cryptosporidiosis infection.

Novel inhibitor of Profilin1 (Pfn1), reducing the overall level of cellular filamentous (F)-actin, slowing EC migration and proliferation, and inhibiting the angiogenic ability of EC both in vitro and ex vivo

Novel inhibitor of Profilin1 (Pfn1), reducing the overall level of cellular filamentous (F)-actin, slowing EC migration and proliferation, and inhibiting the angiogenic ability of EC both in vitro and ex vivo

Water soluble derivative pro-drug of PG490 (triptolide)

Novel anti-HIF-1alpha agent

Potent and selective antagonist of the VIP1 receptor, inhibiting competitively effect of VIP on the VIP1 receptor mediated stimulation of adenylate cyclase activity with Ki values respectively of 15 ± 5 nM and 2 ± 1 nM for the rat and human VIP1 receptor

Novel allosteric PGAM1 inhibitor, showing efficacious in multiple preclinical models of pancreatic ductal adenocarcinoma (PDAC), especially with high PGAM1 expression

Novel allosteric PGAM1 inhibitor, showing efficacious in multiple preclinical models of pancreatic ductal adenocarcinoma (PDAC), especially with high PGAM1 expression

Novel potent matrix metalloproteinase (MMP) inhibitor, targeting MMPs 1, 3, 9, and 13 (24, 18, 1.9, and 1.3 nM, respectively)

Glycolytic enzyme phosphoglycerate mutase 1 (PGAM1) inhibitor

Inhibitor of both Bcr-Abl tyrosine kinase and Aurora kinases

Selective ATP competitive ALK inhibitor

Inhibitor of phagocytosis, interacting with and inhibiting the activating Fc receptors on macrophages, inhibiting downstream signaling pathways driving Fc-mediated phagocytosis

Natural nicotinic acetylcholine receptor agonist

Novel COX-2 inhibitor

Inhibitor of NMDA receptors, used as a veterinary anesthetic, and briefly as a general anesthetic for humans

Selective ligand of a specific G-quadruplex conformation, interacting with the quadruplex through extensive

Prodrug of phenoxodiol

Inhibitor of internalization of cell surface receptors and tyrosine phosphatases, with no effect on tyrosine kinase

Blocker of dsRNA-induced IRF3 nuclear translocation and homodimerization; Inhibitor of lipopolysaccharide-mediated Toll-like receptor-4 signaling; Inhibitor of human pancreatic cancer

Novel selective α-syn ligand, exhibited the promising binding characteristics for α-syn aggregates (Ki = 0.52 nM)

Novel neuropeptide, protecting human brain vascular endothelial cells against oxygen-glucose deprivation/reoxygenation (OGD/R)-induced inflammation and permeability, significantly ameliorating HFD-induced obesity and fatty liver, regulating pituitary gona

Novel GPR173 agonist, promoting osteoblastic differentiation of MC3T3-E1 cells. stimulating mRNAs encoding hypothalamo-pituitary-gonadal hormones

Natural anti-tumor agent, showing strong apoptotic anticancer effects against platinum-resistant solid cancers

Potent antagonist of (H1N1)pdm09 infection, markedly suppressing cytopathic effects and attenuating viral gene expression in (H1N1)pdm09-infected MDCK cells

Sulindac derivative with promising anticancer activities

Inducer of platelet aggregation, playing a role in cellular signal transduction and possibly in cell growth control and carcinogenesis

Novel photoswitchable BET bromodomain Degrader (PHOTAC)

Novel potent photoswitchable antagonist for a precise spatiotemporal control of β2-adrenoceptors

Novel photocontrol inhibitor of the voltage-gated proton channel Hv1

Functionalized photoswitchable cereblon ligand for Degraders

Novel photoswitchable sphingolipid probe, reversibly controlled S1P3-dependent pain hypersensitivity in mice and uniquely suited for the study of S1P biology in cultured cells and in vivo

Novel porphyrazine-based photodynamic anti-cancer agent, inducing immunogenic cell death

Novel porphyrazine-based photodynamic anti-cancer agent, inducing immunogenic cell death

Novel photoswitchable sphingolipid probe

Novel photoswitchable inhibitor of human dihydrofolate reductase

Natural flavonoidal alkaloid from the sea-grass Phyllosphadix iwatensis

Natural cytotoxic withanolide antitumor agent, inducing apoptosis by decreasing mitochondrial membrane potential and elevating the Bax/Bcl-2 protein expression ratio

Natural inhibitor of Wnt signaling, modulating β-catenin-dependent transcription

Platelet aggregation inhibitor

Platelet aggregation inhibitor

Novel Tau ligand, displaying high Tau binding, low MAO-A binding, high brain uptake, and fast and complete brain washout

Novel inhibitor of the PI3K/Akt/mTOR signaling pathways, activating P53 and inducing apoptosis

Novel Inhibitor of the PI3K-Akt Pathway, Inducing Autophagy of Female Germline Stem Cells

Highly potent ATP-competitive PI3Kdelta/Vps34 dual inhibitor

Novel potent PI3K inhibitor with a modified omipalisib structure

Novel PI3K inhibitor, synergizing with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.

Selective 5-HT4 receptor antagonist

Novel Subtype-Selective PPARbeta/delta Agonist

Potent and selective beta2-adrenoceptor agonist

Prodrug of GABA, used for treatment of neurogenic bladder in spinal and benign prostatic hyperplasia

Novel PI3K inhibitor, displaying potent preclinical activity against multiple myeloma